Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Heartburn Clinical Trial

Official title:

An Open-label, Randomized, Crossover Study to Investigate the Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06098742
• Other study ID #: ANT-05-01-2022
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 31, 2024
• Est. completion date: September 20, 2025

Study information

• Verified date: October 2023
• Source: Valenta Pharm JSC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: September 20, 2025
• Est. primary completion date: October 20, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study prior to any of the study procedures;

2. Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive);

3. Verified diagnosis "healthy" (without abnormal findings in the protocol-defined clinical, laboratory, and instrumental test data);

4. pH according to hourly pH-metry in the screening period, carried out at least 3 hours after the last meal, is completely in the range from 1 to 3 inclusive throughout the entire astronomical hour of measurement;

5. Blood pressure (BP) levels: 100 to 139 mm Hg, inclusive (systolic, SBP), 60 to 89 mm Hg, inclusive (diastolic, DBP);

6. Heart rate (HR) of 60 to 90 bpm, inclusive;

7. Body mass index (BMI) of 18.5 kg/m2 = BMI = 30 kg/m2, where the body weight range is = 55 kg for men and = 45 kg for women;

8. Non-smoking healthy volunteers (who have never smoked or gave up smoking more than 6 months prior to the Screening);

9. Consent to use adequate methods of contraception throughout the study and for 30 days after completion; for women of preserved reproductive potential, a negative urine pregnancy test result;

10. The volunteers must have adequate behavior and coherent speech.

Exclusion Criteria:

1. A history of allergy;

2. History of drug intolerance to the active and/or excipients included in the study drugs;

3. History of drug intolerance of or hypersensitivity/allergic reactions to lidocaine, xylocaine or other topical anesthetics which will be used at the trial site for anesthesia during esophagogastroduodenoscopy (EGD) and insertion of the probe for the pH measurements;

4. Chronic diseases of the circulatory, lymphatic, respiratory, nervous, endocrine, gastrointestinal, musculoskeletal, integumentary, immune, urogenital, and hematopoietic systems;

5. Esophageal, gastric, and/or duodenal diseases based on EGC performed at screening and based on the medical history; a history of esophageal, gastric, and/or duodenal surgery;

6. Diseases/conditions which, in the opinion of the investigator, may affect the pH measurement results;

7. Acute infectious diseases less than 4 weeks prior to screening;

8. Use of antacids (including sodium bicarbonate solution)/H2 antagonists 24 h prior to the Screening Visit;

9. Use of proton pump inhibitors 72 h prior to the Screening Visit;

10. Use of (including use of a single dose) steroids and/or other ulcerogenic drug (e.g., nonsteriodal anti-inflammatory drugs [NSAID]) less than 4 weeks prior to the Screening Visit;

11. Regular use of any medicinal products, including prescription only and OTC (Over-the-counter) drugs and dietary supplements within 2 weeks prior to the Screening Visit;

12. Blood or plasma donation less than 3 months prior to the Screening Visit;

13. Use of hormonal contraceptives (in women) less than 2 months prior to the Screening Visit;

14. Pregnancy or breastfeeding; a positive pregnancy test for women of childbearing potential;

15. Participation in another clinical trial less than 3 months prior to screening or simultaneously with this study;

16. Use of more than 10 units of alcohol (1 unit of alcohol is equivalent to 330 ml of beer, 150 ml of wine or 40 ml of spirits) a week within a month prior to the enrollment in the study or history data of alcohol/drug dependence or drug abuse.

17. Positive antibody blood test for HIV-1 and HIV-2, Treponema pallidum antigen, hepatitis B surface antigen (HBsAg), or hepatitis C virus antigen;

18. Positive urine test for narcotic substances or strong drugs;

19. Positive test for alcohol vapor in exhaled breath or a positive alcohol saliva test;

20. Deviated septum/nasal obstruction preventing the placement of the pH probe;

21. Medical history of chronic constipation;

22. Medical history of severe maxillofacial injuries;

23. Expected admission to hospital during this study for any reason, except for hospitalization provided for by this protocol;

24. Impossibility or failure to comply with the protocol, undergo protocol-defined procedures, or adhere to the diet or activity regime;

25. Positive SARS-CoV-2 (severe acute respiratory syndrome related coronavirus) (COVID-19) rapid test;

26. Other circumstances which in the opinion of the investigator prevent a volunteer from being included in the study or may result in premature drop-out from the study.

Withdrawal criteria:

1. The volunteer's refusal to further participate in the study;

2. Failure of the volunteer to comply with the rules of participation in the study (skipping study procedures, independent use of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);

3. Taking prohibited therapy;

4. Occurrence of causes/occurrence during the study of situations that threaten the safety of the volunteer, including severe AEs;

5. Volunteers selected to participate in the study in violation of the inclusion/non-inclusion criteria;

6. Violation of the rules for conducting pH measurements or the occurrence of conditions that required early termination of pH measurements (vomiting, nosebleeds, etc.);

7. Missing a dose of the study drug/comparator drug during any period of the study for any reason;

8. Positive urine test for narcotics and powerful drugs;

9. Positive breath alcohol vapor test or alcohol in saliva;

10. Positive pregnancy test in women;

11. Positive test for COVID-19;

12. The occurrence in the course of the study of other reasons that prevent the study according to the protocol.

Related Conditions & MeSH terms

• Duodenal Ulcer
• Heartburn

Intervention

Drug:
• Antareit
A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake

Locations

Country	Name	City	State
Russian Federation	Llc "Certa Clinic"	Moscow
Russian Federation	Limited Liability Company "Research Center Eco-Safety"	Saint Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Valenta Pharm JSC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacodynamics - AUCpH - Area under the curve potential of hydrogen	Area under the pharmacodynamic pH-time curve	From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics - time percentage during which the intragastric pH value will exceed 4.0	PH - potential of hydrogen	From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics- ??maximum	maximum potential of hydrogen	From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics- ??min	minimum potential of hydrogen	From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics - average pH value	root mean square	From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics - time percentage during which the intragastric pH value will exceed 3.0	During which the intragastric pH value will exceed 3.0	From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics - median time when the pH was above 3.0		From 0 to 1 hour (Day 1 and Day 8)
Primary	Pharmacodynamics - median time when the pH was above 4.0		From 0 to 1 hour (Day 1 and Day 8)
Secondary	Safety and Tolerability: adverse event (AE) number and frequency	Number and frequency of adverse events (AEs) or serious AEs (SAEs)	From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)
Secondary	Safety and Tolerability: serious adverse event (SAE) number and frequency	Number and frequency of serious AEs (SAEs)	From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)
Secondary	Safety and Tolerability: volunteer complaints		From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)
Secondary	Safety and Tolerability: physical examination results	Physical examination will be conducted to identify normal and abnormal physical characteristics of volunteers in accordance with the planned examination and will include an assessment of the Condition of the cardiovascular, respiratory, digestive, endocrine, musculoskeletal, nervous, sensory systems, skin/visible mucous membranes	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 15)
Secondary	Safety and Tolerability: vital signs	systolic blood pressure (SBP),diastolic blood pressure (DBP), heart rate (HR), body temperature	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 15)
Secondary	Safety and Tolerability: 12-lead electrocardiogram (ECG)	12-lead ECG (I, II, III, aVR -enhanced unipolar abduction from the right arm , aVL - enhanced unipolar abduction from the left arm , aVF - enhanced unipolar abduction from the left leg? V1-V6) taken while lying down: heart rate (beats per minute), PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex), QRS complex (The QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram), corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave)	Screening, Day 9
Secondary	Safety and Tolerability: clinical blood test	hemoglobin, hematocrit, Red blood cell count, Platelet count, Leukocyte count, erythrocyte sedimentation rate, Leukocyte formula (myelocytes, band neutrophils, segmented neutrophils, eosinophils, basophils, monocytes, lymphocytes)	Screening, Day 2, Day 9
Secondary	Safety and Tolerability: blood chemistry	Glucose concentration, Total cholesterol concentration, Total protein concentration, Total bilirubin concentration, Creatinine concentration, Alkaline phosphatase activity, alanine transaminase and aspartate transaminase activity	Screening, Day 2, Day 9
Secondary	Safety and Tolerability: urinalysis	Relative density, Color, Transparency, pH, Protein concentration, Glucose concentration, Red blood cell content, White blood cell content, Epithelial cell content, Presence of casts, Presence of mucus, Presence of bacteria.	Screening, Day 2, Day 9
Secondary	Safety and Tolerability: urinalysis (microscopy)	Microscopy of urine sediment is performed if it is present.	Screening, Day 2, Day 9